The in vivo data of CYP46A1 activators on inhibitors of amyloid pathology (Mast et al., 2017b), together with our findings that CYP46A1 activators reduce Tau accumulation in human AD neurons, support the development of allosteric activators of CYP46A1 as therapies for AD. Here, MAPT is linked to Alzheimer disease.